Miliauskas J R, Berard C W, Young R C, Garvin A J, Edwards B K, DeVita V T
Cancer. 1982 Nov 15;50(10):2115-21. doi: 10.1002/1097-0142(19821115)50:10<2115::aid-cncr2820501024>3.0.co;2-9.
A retrospective study of 66 cases of undifferentiated non-Hodgkin's lymphomas at the National Cancer Institute over a 22-year period suggests that the histologic distinction between Burkitt's and non-Burkitt's types is clinicopathologically meaningful. Thirty-nine patients with Burkitt's lymphoma had a median age at presentation of ten years. The primary site of disease in these patients was more commonly extranodal; at the time of diagnosis 26 (66%) of these cases revealed intra-abdominal involvement; 25 (64%) of the cases were Stage IV. The 27 patients with non-Burkitt's lymphomas had a median age at presentation of 34 years; the primary site of disease was more commonly nodal (peripheral adenopathy was often present at the time of diagnosis); only nine (33%) of the cases were Stage IV. Median survival was essentially equivalent in the two groups, 9.5 months for Burkitt's lymphoma and 10.0 months for the non-Burkitt's lymphoma. Overall, survival was not significantly different among the two patient populations; however, patients with Burkitt's lymphoma had a longer survival than those with non-Burkitt's lymphoma. Estimates of five-year survival (with 95% confidence) are 42% for Burkitt's lymphoma and 11% for non-Burkitt's lymphoma, respectively, which are significantly different (P = 0.01).
一项对美国国立癌症研究所22年间66例未分化非霍奇金淋巴瘤病例的回顾性研究表明，伯基特型和非伯基特型之间的组织学区分在临床病理上具有重要意义。39例伯基特淋巴瘤患者就诊时的中位年龄为10岁。这些患者的疾病原发部位更常见于结外；在诊断时，其中26例（66%）显示有腹腔内受累；25例（64%）为IV期。27例非伯基特淋巴瘤患者就诊时的中位年龄为34岁；疾病原发部位更常见于淋巴结（诊断时外周淋巴结病常存在）；仅9例（33%）为IV期。两组的中位生存期基本相当，伯基特淋巴瘤为9.5个月，非伯基特淋巴瘤为10.0个月。总体而言，两组患者的生存率无显著差异；然而，伯基特淋巴瘤患者的生存期比非伯基特淋巴瘤患者长。伯基特淋巴瘤和非伯基特淋巴瘤的五年生存率估计值（95%置信区间）分别为42%和11%，二者有显著差异（P = 0.01）。
